HALO - Halozyme proposes offering of $500M convertible senior notes due 2027

Halozyme Therapeutics (HALO) announces that it intends to offer $500M aggregate principal amount of convertible senior notes due 2027.The company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $75M aggregate principal amount of convertible notes.The convertible notes will mature on March 1, 2027, unless earlier redeemed, repurchased or converted in accordance with their terms, Halozyme said.Halozyme expects to use a portion of the net proceeds to enter into privately negotiated agreements with certain holders of its outstanding 1.25% convertible senior notes due 2024 to exchange their existing convertible notes for a combination of cash and shares.

For further details see:

Halozyme proposes offering of $500M convertible senior notes due 2027